Vedanta Biosciences to Present at Chardan’s 2022 Metagenomics and Microbiome Medicines Summit
Chardan’s 2022 Metagenomics and Microbiome Medicines Summit
Date:
Panel Title: Great Debate - Is the Term “Microbiome” Drug Development Passé?
Panel Time:
Presentation Time:
About Vedanta Biosciences
Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks. The company’s clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel diseases, advanced or metastatic cancers, and food allergy. These investigational therapies are grounded in pioneering research – published in leading journals including Science, Nature, and Cell – to identify beneficial bacteria that live symbiotically within the healthy human gut, fight pathogens and induce a range of potent immune responses. Vedanta Biosciences controls a foundational portfolio of more than 40 patents and has built what it believes to be the world’s biggest library of bacteria derived from the human microbiome. Proprietary capabilities include deep expertise in consortium design, vast datasets from human interventional studies and cGMP-compliant manufacturing of oral live biotherapeutic candidates containing pure, clonally derived bacterial consortia in powdered form. Vedanta Biosciences was founded by
View source version on businesswire.com: https://www.businesswire.com/news/home/20220223006319/en/
Investors and Media
+1 617 835 9304
Chris.Brinzey@westwicke.com
Source: Vedanta Biosciences
